Pharmaceuticals · NLL
Pharma - API & CRAMS
from 19,956 today
Neuland beat consensus Q1FY27 revenue/EBITDA/PAT by 24%/72%/69%, driven by growth across segments, particularly in the high-margin CMS segment. We raise our FY27E/28E EPS by 20%/8% and retain 'BUY' with a TP of INR24,100.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
